You are here: Industry Insights > myeloma

News List

Novel Therapy Treats Triple-Class Refractory Multiple Myeloma drugs
August 26, 2019
The combination of selinexor and dexamethasone seems effective in treating patients with multiple myeloma that has not responded to standard therapies...
Patient Preferences Explored in Multiple Myeloma Treatment drugs
August 21, 2019
An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM)...
SAVED Score Can Predict Risk for VTE in Multiple Myeloma drugs
August 19, 2019
For patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), a risk assessment model, SAVED, can predict the risk for venous thromboembolism (VTE)...
Cost Burden of Disease Progression High in Multiple Myeloma drugs
August 16, 2019
The economic burden of disease progression is considerable among multiple myeloma (MM) patients receiving drug therapy across all lines of therapy (LOTs)...
New Score Predicts Risk for VTE in Those With Multiple Myeloma drugs
August 08, 2019
A new risk prediction score outperforms current guidelines for predicting venous thromboembolism (VTE) in multiple myeloma (MM), according to a study published online in the American Journal of Hematology
MGUS Can Progress to Multiple Myeloma Within Five Years drugs
July 24, 2019
Individuals with low- or intermediate-risk monoclonal gammopathy of undetermined significance (MGUS) can experience progression...
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma worldpharmanews
July 11, 2019
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma.
Xpovio With Dexamethasone Approved for Refractory Multiple Myeloma drugs
July 10, 2019
Xpovio With Dexamethasone Approved for Refractory Multiple Myeloma.
Karyopharm’s Xpovio nabs myeloma nod despite checkered past fiercepharma
July 09, 2019
Karyopharm finally got its much-needed first commercial approval for a drug that has stirred up safety concerns—and suffered plenty of speed bumps—along the way. Now the company must cope with a limited FDA nod, and with a brand-new marketing chief to boo
FDA approves new treatment for refractory multiple myeloma worldpharmanews
July 05, 2019
FDA approves new treatment for refractory multiple myeloma.

Previous page 1 2 3 4 Next page